Contineum CSO sells 4,170 shares in plan trade

Contineum Therapeutics, Inc. Chief Scientific Officer Daniel S. Lorrain reported an open-market sale of Class A common stock.

Rhea-AI Filing Summary

Contineum Therapeutics, Inc. Chief Scientific Officer Daniel S. Lorrain reported an open-market sale of Class A common stock. He sold 4,170 shares on March 2, 2026 at a weighted average price of $15.0084 per share, in multiple trades between $14.60 and $15.41.

The sale was carried out under a pre-arranged Rule 10b5-1 trading plan adopted on September 23, 2025. After this transaction, Lorrain directly holds 151,882 shares of Class A common stock, and an additional 6,842 shares are held indirectly by his spouse.

Insider Trade Summary

Net Seller: 4,170 shares

Net Sell 2 txns

Insider Lorrain Daniel S.

Role Chief Scientific Officer

Sold 4,170 shs ($63K)

Type	Security	Shares	Price	Value
Sale	Class A Common Stock	4,170	$15.0084	$63K
holding	Class A Common Stock	--	--	--

Holdings After Transaction: Class A Common Stock — 151,882 shares (Direct); Class A Common Stock — 6,842 shares (Indirect, By Spouse)

Footnotes (2)

1. F1. These transactions were effected pursuant to a 10b5-1 trading plan adopted by the reporting person on September 23, 2025.
2. F2. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $14.60 to $15.41, inclusive. The reporting person undertakes to provide to Issuer, any security holder of Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote to this Form 4.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did Contineum Therapeutics (CTNM) report for its CSO?

Contineum Therapeutics reported that Chief Scientific Officer Daniel S. Lorrain sold 4,170 shares of Class A common stock. The shares were sold in open-market transactions at a weighted average price of $15.0084 per share on March 2, 2026.

At what prices did the CTNM insider shares trade in the March 2, 2026 sale?

The reported weighted average sale price was $15.0084 per share. According to the disclosure, individual trades occurred at prices ranging from $14.60 to $15.41 per share, all executed on March 2, 2026 in open-market transactions.

Was the CTNM insider sale by Daniel S. Lorrain under a 10b5-1 plan?

Yes. The filing states the transactions were executed under a Rule 10b5-1 trading plan. This pre-arranged plan was adopted by Daniel S. Lorrain on September 23, 2025, allowing scheduled sales independent of day-to-day trading decisions.

How many Contineum Therapeutics (CTNM) shares does the CSO hold after the sale?

After the reported sale, Daniel S. Lorrain directly owns 151,882 shares of Class A common stock. The filing also notes an additional 6,842 shares of Class A common stock are held indirectly through his spouse.

What type of security did the Contineum Therapeutics insider sell?

The insider sale involved Contineum Therapeutics Class A common stock. All disclosed transactions in the filing relate to this same class of equity security, sold in open-market transactions at a range of prices on March 2, 2026.

How many CTNM shares were sold versus retained in this insider transaction?

The filing reports that 4,170 shares of Class A common stock were sold by Daniel S. Lorrain. Following the sale, he retains 151,882 shares directly, with a further 6,842 shares held indirectly through his spouse.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 03/02/2026 - 06:30 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Lorrain Daniel S.

(Last) (First) (Middle)

3565 GENERAL ATOMICS COURT, SUITE 200

(Street)

SAN DIEGO CA 92121

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Contineum Therapeutics, Inc. [ CTNM ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Scientific Officer

3. Date of Earliest Transaction (Month/Day/Year)
03/02/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Class A Common Stock	03/02/2026		S(1)		4,170	D	$15.0084(2)	151,882	D
Class A Common Stock								6,842	I	By Spouse

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. These transactions were effected pursuant to a 10b5-1 trading plan adopted by the reporting person on September 23, 2025.

2. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $14.60 to $15.41, inclusive. The reporting person undertakes to provide to Issuer, any security holder of Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote to this Form 4.

	/s/ Peter Slover, Attorney-in-Fact	03/02/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.